Format

Send to

Choose Destination
Front Cell Dev Biol. 2017 Apr 11;5:35. doi: 10.3389/fcell.2017.00035. eCollection 2017.

In vivo Reprogramming of Cancer Metabolism by MYC.

Author information

1
Department of Cell and Tissue Biology, University of California, San FranciscoSan Francisco, CA, USA.
2
Biomedical Sciences Graduate Program, University of California, San FranciscoSan Francisco, CA, USA.
3
Department of Medicine, University of California, San FranciscoSan Francisco, CA, USA.
4
Helen Diller Family Comprehensive Cancer Center, University of California, San FranciscoSan Francisco, CA, USA.

Abstract

The past few decades have welcomed tremendous advancements toward understanding the functional significance of altered metabolism during tumorigenesis. However, many conclusions drawn from studies of cancer cells in a dish (i.e., in vitro) have been put into question as multiple lines of evidence have demonstrated that the metabolism of cells can differ significantly from that of primary tumors (in vivo). This realization, along with the need to identify tissue-specific vulnerabilities of driver oncogenes, has led to an increased focus on oncogene-dependent metabolic programming in vivo. The oncogene c-MYC (MYC) is overexpressed in a wide variety of human cancers, and while its ability to alter cellular metabolism is well-established, translating the metabolic requirements, and vulnerabilities of MYC-driven cancers to the clinic has been hindered by disparate findings from in vitro and in vivo models. This review will provide an overview of the in vivo strategies, mechanisms, and conclusions generated thus far by studying MYC's regulation of metabolism in various cancer models.

KEYWORDS:

MYC; fatty acid oxidation; glucose; glutamine; metabolism; ras proteins; therapeutic irrigation; transgenic cancer models

Supplemental Content

Full text links

Icon for Frontiers Media SA Icon for PubMed Central
Loading ...
Support Center